Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Pharmacokinetics of fosfomycin: a study in patients with prolonged treatment for urinary tract infection

    Summary
    EudraCT number
    		 2018-000616-25
    Trial protocol
    		 NL  
    Global end of trial date
    01 Jan 2020

    Results information
    Results version number
    		 v1(current)
    This version publication date
    25 Dec 2021
    First version publication date
    25 Dec 2021
    Other versions

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    T17-084
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 -
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Haga Teaching Hospital
    Sponsor organisation address
    Els Borst-Eijlersplein 245, The Hague, Netherlands,
    Public contact
    S.G. Kuiper, Haga Teaching Hospital, s.g.kuiper@lumc.nl
    Scientific contact
    S.G. Kuiper, Haga Teaching Hospital, s.g.kuiper@lumc.nl
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    07 Feb 2020
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    01 Oct 2019
    Global end of trial reached?
    Yes
    Global end of trial date
    01 Jan 2020
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To evaluate the pharmacokinetics of fosfomycine in patients with prolonged fosfomycin therapy to treat urinary tract infection
    Protection of trial subjects
    none
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    01 Apr 2018
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Netherlands: 12
    Worldwide total number of subjects
    12
    EEA total number of subjects
    12
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    5
    From 65 to 84 years
    7
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 Recruitment was done from July 2019 till September 2019 in Haga Teaching Hospital, The Hague, The Netherlands

    Pre-assignment
    Screening details
    		 15 patients were screened and 12 were included in the trial.

    Period 1
    Period 1 title
    Overall trial (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Not applicable
    Blinding used
    		 Not blinded

    Arms
    Arm title
    		 Fosfomycin
    Arm description
    		 -
    Arm type
    		 Experimental

    Investigational medicinal product name
    Fosfomycin
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for oral solution in sachet
    Routes of administration
    Oral use
    Dosage and administration details
    3 gram once

    Investigational medicinal product name
    Fosfomycin
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for infusion
    Routes of administration
    Intravenous bolus use
    Dosage and administration details
    3 gram intravenous

    Number of subjects in period 1
    		Fosfomycin
    Started
    12
    Completed
    12

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Overall trial
    Reporting group description
    		 -

    Reporting group values
    		 Overall trial Total
    Number of subjects
    		 12 12
    Age categorical
    Units: Subjects
        In utero
    		 0
        Preterm newborn infants (gestational age < 37 wks)
    		 0
        Newborns (0-27 days)
    		 0
        Infants and toddlers (28 days-23 months)
    		 0
        Children (2-11 years)
    		 0
        Adolescents (12-17 years)
    		 0
        Adults (18-64 years)
    		 0
        From 65-84 years
    		 0
        85 years and over
    		 0
    Age continuous
    Units: years
        median (full range (min-max))
    		 66 (44 to 76) -
    Gender categorical
    Units: Subjects
        Female
    		 9 9
        Male
    		 3 3
    BMI
    Units: kg/m2
        median (full range (min-max))
    		 26.8 (20.4 to 28.7) -
    Renal function (eGFR)
    Units: ml/min/1.73 m2
        median (full range (min-max))
    		 83 (63 to 103) -

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Fosfomycin
    Reporting group description
    		 -

    Primary: Fosfomycin serum concentrations

    		 Close Top of page
    End point title
    		 Fosfomycin serum concentrations [1]
    End point description
    End point type
    Primary
    End point timeframe
    -
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis is done.
    End point values
    		 Fosfomycin
    Number of subjects analysed
    12
    Units: mg/L
        number (not applicable)
    12
    Attachments
    		 Untitled (Filename: 20200120.IndividualPlotsLog.Model60.png)
    No statistical analyses for this end point

    Primary: Pharmacokinetic parameters

    		 Close Top of page
    End point title
    		 Pharmacokinetic parameters [2]
    End point description
    End point type
    Primary
    End point timeframe
    -
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis is done.
    End point values
    		 Fosfomycin
    Number of subjects analysed
    12
    Units: parameter estimate
    12
    Attachments
    		 Untitled (Filename: Figuur 2 2020-01-20- Predictions - VPC_Jasper.png)
    No statistical analyses for this end point

    Primary: Urine fosfomycin concentration at day 1

    		 Close Top of page
    End point title
    		 Urine fosfomycin concentration at day 1 [3]
    End point description
    End point type
    Primary
    End point timeframe
    -
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis is done.
    End point values
    		 Fosfomycin
    Number of subjects analysed
    12
    Units: mg/L
        geometric mean (standard deviation)
    622.3 ( 335.1 )
    No statistical analyses for this end point

    Primary: Urine fosfomycine concentration at day 2

    		 Close Top of page
    End point title
    		 Urine fosfomycine concentration at day 2 [4]
    End point description
    End point type
    Primary
    End point timeframe
    -
    Notes
    [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis is done.
    End point values
    		 Fosfomycin
    Number of subjects analysed
    12
    Units: mg/L
        geometric mean (standard deviation)
    41.4 ( 17.1 )
    No statistical analyses for this end point

    Primary: Urine fosfomycin concentration at day 3

    		 Close Top of page
    End point title
    		 Urine fosfomycin concentration at day 3 [5]
    End point description
    End point type
    Primary
    End point timeframe
    -
    Notes
    [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis is done.
    End point values
    		 Fosfomycin
    Number of subjects analysed
    12
    Units: mg/L
        geometric mean (standard deviation)
    20.5 ( 45.6 )
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    1 month
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    24.1
    Reporting groups
    Reporting group title
    Fosfomycin
    Reporting group description
    		 -

    Serious adverse events
    		 Fosfomycin
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 12 (0.00%)
         number of deaths (all causes)
    0
         number of deaths resulting from adverse events
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 Fosfomycin
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    8 / 12 (66.67%)
    Nervous system disorders
    Headache
         subjects affected / exposed
    7 / 12 (58.33%)
         occurrences all number
    7
    General disorders and administration site conditions
    Tiredness
         subjects affected / exposed
    8 / 12 (66.67%)
         occurrences all number
    8
    Gastrointestinal disorders
    Gastro-intestinal complaints
         subjects affected / exposed
    8 / 12 (66.67%)
         occurrences all number
    8

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 07:36:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA